TimePie Longevity Forum Spotlights Evidence-Based Medicine

Key Takeaways

• Forum gathers ~2,000 experts in Shanghai to advance longevity medicine
• China’s 60+ population hits 323 million, boosting geriatric care demand
• TimePie grants fund 3–4 early-stage longevity projects worldwide
• White paper outlines clinic value chain for regulators and investors
• Hainan Boao Lecheng zone fast-tracks overseas therapies for clinical trials

Pulse Analysis

China’s demographic shift is the engine behind the world’s fastest‑growing longevity market. By the end of 2025, more than 323 million Chinese citizens were aged 60 or older, representing nearly a quarter of the population. This surge is prompting both public hospitals and private health groups to launch dedicated geriatric clinics, invest in biomarker tracking, and explore preventive interventions that go beyond traditional anti‑aging cosmetics. The scale of demand is attracting global biotech firms and Swiss clinics eager to test therapies in China’s special‑access zones, such as the Hainan Boao Lecheng Pilot Zone, which streamlines entry for overseas‑approved drugs and devices.

The 7th TimePie Longevity Forum positions itself as the connective tissue linking cutting‑edge research with market execution. Featuring 40‑50 international speakers, the agenda moves from deep‑dive sessions on stem‑cell regeneration, epigenetic reprogramming and metabolic dysfunction to pragmatic discussions on commercializing diagnostics, pricing prevention services, and navigating cross‑border regulatory pathways. A newly released white paper, co‑authored with Fudan University, maps the entire clinic ecosystem—from digital assessment platforms to physical treatment spaces—offering investors and operators a clear blueprint for scaling responsible longevity care in China and beyond.

Beyond knowledge sharing, the forum fuels the innovation pipeline through its Longevity Research Grant. Net proceeds are earmarked for three to four early‑stage projects worldwide, covering areas like senescent cell clearance and AI‑driven drug discovery. This funding model creates a feedback loop where industry growth directly supports scientific validation, ensuring that emerging therapies are grounded in robust evidence before reaching patients. For investors, clinicians, and technology providers, the event represents a strategic entry point into a market where scientific credibility and commercial viability are increasingly intertwined.